November 9 2022
Day Zero Diagnostics appoints Gail Marcus to its Board of Directors as an independent director.
October 24 2022
Day Zero Diagnostics receives an $8.2 million award in optional stage funding from CARB-X.
October 21 2022
Day Zero receives $8.2M from CARB-X to speed development of infectious disease diagnostics.
October 20 2022
Additional CARB-X funding supports the transition into product development of the firm's whole-genome sequencing and machine learning-based approach to antimicrobial resistance profiling.
January 5 2022
Learn how we are predicting antimicrobial susceptibility directly from blood using whole-genome sequencing with Day Zero Diagnostic's Scientific Co-founder, Melis Anahtar, MD, Phd.
January 4 2022
Day Zero Diagnostics was featured in AACC's December issue of "Clinical Laboratory News", highlighting our work around whole genome sequencing and machine learning for rapid diagnosis of infections directly from blood.